Avondale Partners Downgrades Amedisys (AMED) to Underperform
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 19 | New: 38
Join SI Premium – FREE
Avondale Partners downgraded Amedisys (NASDAQ: AMED) from Market Perform to Underperform, price target lowered from $15 to $8.
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Shares of Amedisys closed at $10.06 yesterday.
For more ratings news on Amedisys click here and for the rating history of Amedisys click here.
Shares of Amedisys closed at $10.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Ducommun (DCO) to Sector Perform
- Wolfe Research Downgrades Pentair (PNR) to Peerperform
- Wolfe Research Downgrades Arthur J. Gallagher (AJG) to Peerperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Avondale PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
